+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasal Polyps - Pipeline Review, H2 2019

  • ID: 4866564
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 102 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AnaptysBio Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose US Inc
  • MORE
Nasal Polyps - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides an overview of the Nasal Polyps (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 4, 3 and 2 respectively.

Nasal Polyps (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasal Polyps (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AnaptysBio Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose US Inc
  • MORE
Introduction
Report Coverage
Nasal Polyps (Nasal Polyposis) - Overview
Nasal Polyps (Nasal Polyposis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
AnaptysBio Inc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
Kyowa Kirin Co Ltd
Novartis AG
OptiNose US Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Suzhou Connect Biopharmaceuticals Ltd
Nasal Polyps (Nasal Polyposis) - Drug Profiles
ACT-774312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etokimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasal Polyps (Nasal Polyposis) - Dormant Projects
Nasal Polyps (Nasal Polyposis) - Discontinued Products
Nasal Polyps (Nasal Polyposis) - Product Development Milestones
Featured News & Press Releases
Oct 30, 2019: EC approves Dupixent’s indication in chronic rhinosinusitis
Sep 20, 2019: Sanofi : CHMP recommends approval of Dupixent (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
Sep 20, 2019: The Lancet publishes results from two positive phase 3 trials of Dupixent (dupilumab) in severe chronic Rhinosinusitis with Nasal Polyps
Sep 12, 2019: Optinose announces $150 million debt financing from Pharmakon
Jun 27, 2019: FDA approves Regeneron’s antibody Dupixent for nasal polyposis
Jun 26, 2019: FDA approves first treatment for chronic rhinosinusitis with nasal polyps
Jun 03, 2019: Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
May 07, 2019: Dupixent Filed for Sinusitis in Japan: Sanofi
Mar 11, 2019: FDA grants priority review for Sanofi’s Dupixent to treat rhinosinusitis
Feb 19, 2019: Optinose announces issuance of four additional U.S. patents covering XHANCE
Feb 15, 2019: Optinose to highlight data at the 2019 AAAAI Annual Meeting in San Francisco
Dec 10, 2018: Optinose announces first patient enrolled in clinical trial of XHANCE for Chronic Sinusitis
Oct 18, 2018: Sanofi’s Dupixent meets Phase III trial endpoints for rhinosinusitis
Oct 03, 2018: Optinose to highlight data at two upcoming scientific meetings
Aug 30, 2018: European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H2 2019
Table 9: Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Table 10: Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 11: Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Table 12: Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, H2 2019
Table 13: Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H2 2019
Table 14: Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose US Inc, H2 2019
Table 15: Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H2 2019
Table 16: Nasal Polyps (Nasal Polyposis) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Table 17: Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019
Table 18: Nasal Polyps (Nasal Polyposis) - Dormant Projects, H2 2019
Table 19: Nasal Polyps (Nasal Polyposis) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AnaptysBio Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Idorsia Pharmaceutical Ltd
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose US Inc
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Suzhou Connect Biopharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll